Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/a-case-of-fatal-cetuximab-induced-interstitial-lung-disease-during-the-Vis0BW7csO
References (25)
-
R. Greenlee, Taylor Murray, Sherry Bolden, P. Wingo (2000)
Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 50
-
M. Cohen, Grant Williams, R. Sridhara, Gang Chen, R. Pazdur (2003)
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.The oncologist, 8 4
-
S. Danson, F. Blackhall, P. Hulse, M. Ranson (2005)
Interstitial Lung Disease in Lung CancerDrug Safety, 28
-
D. Parkin, F. Bray, J. Ferlay, P. Pisani (2005)
Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 55
-
H. Lenz (2007)
Management and preparedness for infusion and hypersensitivity reactions.The oncologist, 12 5
-
Y Achermann, T Frauenfelder, S Obrist, K Zaugg, N Corti, HF Gunthard (2012)
A rare but severe pulmonary side effect of cetuximab in two patientsBMJ Case Rep
-
J. Tabernero, E. Cutsem, E. Díaz-Rubio, A. Cervantes, Y. Humblet, T. André, J. Laethem, P. Soulié, E. Casado, C. Verslype, J. Valera, G. Tortora, F. Ciardiello, O. Kisker, A. Gramont (2007)
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 33
-
E. Cutsem, C. Köhne, E. Hitre, J. Zaluski, Chung-Rong Chien, A. Makhson, G. D'Haens, T. Pintér, R. Lim, G. Bodoky, J. Roh, G. Folprecht, P. Ruff, C. Stroh, S. Tejpar, M. Schlichting, J. Nippgen, P. Rougier (2009)
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.The New England journal of medicine, 360 14
-
H. Fukuda (2000)
European Organization for Research and Treatment of Cancer.Japanese journal of clinical oncology, 30 3
-
F. Fiore, F. Blanchard, F. Charbonnier, F. Pessot, A. Lamy, M. Galais, L. Bastit, Audrey Killian, R. Sesboüé, J. Tuech, A. Queuniet, B. Paillot, J. Sabourin, Francis Michot, Pierre Michel, T. Frebourg (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBritish Journal of Cancer, 96
-
T. Takano, Y. Ohe, M. Kusumoto, U. Tateishi, Seiichiro Yamamoto, H. Nokihara, N. Yamamoto, I. Sekine, H. Kunitoh, T. Tamura, T. Kodama, N. Saijo (2004)
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.Lung cancer, 45 1
-
A. Jemal, F. Bray, Melissa Center, J. Ferlay, Elizabeth Ward, D. Forman (2011)
Global cancer statisticsCA: A Cancer Journal for Clinicians, 61
-
I. Dimopoulou, A. Bamias, P. Lyberopoulos, M. Dimopoulos (2006)
Pulmonary toxicity from novel antineoplastic agents.Annals of oncology : official journal of the European Society for Medical Oncology, 17 3
-
J. Wils, T. Sahmoud, A. Sobrero, H. Bleiberg, S. Ahmedzai, J. Blazeby, G. Blijham, T. Conroy, D. Cunningham, D. Curran, E. Díaz-Rubio, M. Ducreux, J. Evans, B. Glimelius, G. Hutchinson, D. Kerr, G. Kiebert, H. Köhne, R. Labianca, R. Langendijk, D. Nitti, B. Nordlinger, P. Rougier, W. Scheithauer, H. Schmoll, E. Cutsem, T. Wagener, J. Wilke, A. Marinus, P. Therasse (1998)
Evaluation of Clinical Efficacy of New Medical Treatments in Advanced Colorectal Cancer. Results of a Workshop Organized by the Eortc GitccgTumori Journal, 84
-
M. Ishiguro, Toshiaki Watanabe, K. Yamaguchi, T. Satoh, Hideyuki Ito, T. Seriu, Y. Sakata, K. Sugihara (2012)
A Japanese Post-marketing Surveillance of Cetuximab (Erbitux®) in Patients with Metastatic Colorectal CancerJapanese Journal of Clinical Oncology, 42
-
J Wils, T Sahmoud, A Sobrero, H Bleiberg, S Ahmedzai, J Blazeby, G Blijham, T Conroy, D Cunningham, D Curran, E Diaz-Rubio, M Ducreux, J Evans, B Glimelius, G Hutchinson, D Kerr, G Kiebert, H Kohne, R Labianca, R Langendijk, D Nitti, B Nordlinger, P Rougier, W Scheithauer, P Therasse (1998)
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative GroupTumori, 84
-
T. Troiani, S. Zappavigna, E. Martinelli, S. Addeo, P. Stiuso, F. Ciardiello, M. Caraglia (2013)
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistanceExpert Opinion on Biological Therapy, 13
-
L. Leard, B. Cho, K. Jones, S. Hays, W. Tope, J. Golden, C. Hoopes (2007)
Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 26 12
-
A. Lièvre, J. Bachet, D. Corre, V. Boige, B. Landi, J. Emile, J. Côté, G. Tomasic, C. Penna, M. Ducreux, P. Rougier, F. Penault-Llorca, P. Laurent-Puig (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.Cancer research, 66 8
-
Y. Achermann, T. Frauenfelder, S. Obrist, K. Zaugg, N. Corti, H. Günthard (2012)
Findings that shed new light on the possible pathogenesis of a disease or an adverse effect A rare but severe pulmonary side effect of cetuximab in two patients -
W. Chua, M. Peters, R. Loneragan, S. Clarke (2009)
Cetuximab-associated pulmonary toxicity.Clinical colorectal cancer, 8 2
-
H. Kindler, K. Shulman (2001)
Metastatic colorectal cancerCurrent Treatment Options in Oncology, 2
-
S Danson, F Blackhall, P Hulse, M Ranson (2005)
Interstitial lung disease in lung cancer: separating disease progression from treatment effectsDrug Saf Int J Med Toxicol Drug Experience, 28
-
J. Hoag, A. Azizi, T. Doherty, Jason Lu, R. Willis, Mark Lund (2009)
Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive reviewJournal of Experimental & Clinical Cancer Research : CR, 28
-
G. Folprecht, M. Lutz, P. Schöffski, T. Seufferlein, A. Nolting, P. Pollert, C. Köhne (2006)
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology, 17 3
- Publisher
- Springer Journals
- Copyright
- Copyright © 2013 by Springer-Verlag France
- Subject
- Medicine & Public Health; Oncology; Biomedicine general
- ISSN
- 1776-2596
- eISSN
- 1776-260X
- DOI
- 10.1007/s11523-013-0295-4
- pmid
- 24114566
- Publisher site
- See Article on Publisher Site
Abstract
Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor. It has demonstrated activity against a number of cancers including lung, head and neck, and colorectal. The most common side effects associated with this agent are dermatological; however, other types of toxicities have been reported with varying frequencies. Here, we report a case of interstitial lung disease that developed within the first 4 weeks of cetuximab treatment initiation in a patient with metastatic colorectal cancer and led to patient death. Early fatal pulmonary events secondary to cetuximab is rarely reported in the literature; this case report highlights the importance of awareness among treating health care professionals of this potentially fatal toxicity.
Journal
Targeted Oncology – Springer Journals
Published: Oct 10, 2013